Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25145959 | 0.91 | GBA1 (0.47) | HRH4HRH3KDM1AMAOAMAOB | |
| SCHEMBL21409195 | 0.79 | LOXL2 (0.49) | HRH4HRH3GBA1 | |
| SCHEMBL21608333 | 0.79 | LOXL2 (0.49) | HRH4HRH3GBA1 | |
| SCHEMBL20281953 | 0.78 | HRH4 (0.43) | HRH4HRH3KDM1APIK3CA | |
| SCHEMBL20281864 | 0.78 | HRH4 (0.45) | HRH4HRH3KDM1AGBA1 | |
| SCHEMBL8227791 | 0.77 | HTR2C (0.49) | HRH4HRH3GBA1 | |
| SCHEMBL28933802 | 0.77 | HTR2C (0.49) | HRH4HRH3GBA1 | |
| SCHEMBL12838122 | 0.77 | KDM1A (0.42) | HRH3KDM1AMAOAMAOBDAO | |
| SCHEMBL21607908 | 0.77 | DAO (0.43) | KDM1AMAOAMAOBPIK3CADAO | |
| SCHEMBL25145964 | 0.77 | CYP3A4 (0.38) | KDM1AMAOAMAOBDAOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HRH4 4152/4885HRH3 3480/4885KDM1A 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.